Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: A conceptual framework

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 1, 2010, Pages 2-12

  Dahl, Svein G ^a   Aarons, Leon ^b   Gundert Remy, Ursula ^c   Karlsson, Mats O ^d   Schneider, Yves Jacques ^e   Steimer, Jean Louis ^f   Trocóniz, Iñaki F ^g  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; XENOBIOTIC AGENT;

BIOMECHANICS; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; EMPIRICISM; HUMAN; MALE; MATHEMATICAL ANALYSIS; MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMS BIOLOGY;

ANIMALS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

ANIMALIA;

EID: 73649142111     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00456.x     Document Type: Short Survey

References (49)

1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000 40 : 67 95.
2. Biomarkers-Definitions-Working-Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacol Ther 2001 69 : 89 95.
3. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002 1 : 727 730.
4. Dahl SG, Sylte I, Ravna AW. Structures and models of transporter proteins. J Pharmacol Exp Ther 2004 309 : 853 860.
5. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000 289 : 739 745.
6. Dahl SG, Sylte I. Molecular modelling of drug targets: the past, the present and the future. Basic Clin Pharmacol Toxicol 2005 96 : 151 155.
7. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007 450 : 383 387.
8. Bonacci TM, Mathews JL, Yuan C, Lehmann DM, Malik S, Wu D et al. Differential targeting of Gβγ-subunit signaling with small molecules. Science 2006 312 : 443 446.
9. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006 5 : 660 670.
10. Barton S. Simulating schizophrenia. Nat Rev Drug Discov 2006 5 : 281.
11. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006 49 : 603 615.
12. Barton HA, Chiu WA, Woodrow Setzer R, Andersen ME, Bailer AJ, Bois FY et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci 2007 99 : 395 402.
13. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C et al. Physiologically-based kinetic modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern Lab Anim 2007 35 : 661 671.
14. Clewell RA, Clewell HJ III. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol 2008 50 : 129 143.
15. Loizou G, Spendiff M, Barton HA, Bessems J, Bois FY, d'Yvoire MB et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol 2008 50 : 400 411.
16. Levy G. Kinetics of pharmacologic effects. Clin Pharmacol Ther 1966 7 : 362 372.
17. Gibaldi M, Levy G, Hayton W. Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man. Anesthesiology 1972 36 : 213 218.
18. Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1969 10 : 22 35.
19. Åblad B, MErvik M, Hallgren J, Johnson G, Sölvell L. Pharmacological effects and serum levels of orally administered alprenolol in man. Eur J Clin Pharmacol 1972 5 : 44 52.
20. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993 21 : 457 478.
21. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003 31 : 510 518.
22. Noble D. Modeling the heart-from genes to cells to the whole organ. Science 2002 295 : 1678 1682.
23. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981 6 : 429 453.
24. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992 51 : 715 728.
25. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther 1998 64 : 622 635.
26. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G et al. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther 2000 68 : 617 625.
27. Sallstrom B, Visser SA, Forsberg T, Peletier LA, Ericson AC, Gabrielsson J. A pharmacodynamic turnover model capturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal-handling effects. J Pharmacokinet Pharmacodyn 2005 32 : 835 859.
28. Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001 41 : 625 659.
29. Holford NHG, Mould DR, Peck CC. Disease progress models. In : Atkinson A (ed Principles of Clinical Pharmacology. Academic Press, San Diego, 2001 253 262.
30. Schuttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D et al. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987 15 : 241 253.
31. Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 1992 260 : 36 44.
32. Pedraz JL, Calvo B, Smithers JA, Thompson GA. Pharmacokinetic- pharmacodynamic modeling: time-dependent protein binding-an alternative interpretation of clockwise and counterclockwise hysteresis. J Pharm Sci 1992 81 : 232 236.
33. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979 25 : 358 371.
34. Troconiz IF, Wolters JM, Tillmann C, Schaefer HG, Roth W. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. Clin Pharmacokinet 2006 45 : 715 728.
35. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998 45 : 229 239.
36. Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988 244 : 231 236.
37. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 1995 274 : 921 927.
38. Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther 1997 281 : 1238 1246.
39. Gardmark M, Brynne L, Hammarlund-Udenaes M, Karlsson MO. Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 1999 36 : 145 167.
40. Francheteau P, Merdjan H, Guerret M, Kirkesseli S, Sassano P, Steimer JL. Prediction of hemodynamic responses in hypertensive and elderly subjects from healthy volunteer data: the example of intravenous nicardipine. In : Kimko HC, Duffull SB (eds). Simulation for Designing of Clinical Trials. Marcel Dekker, New York, 2002 327 351.
41. Francheteau P, Steimer JL, Merdjan H, Guerret M, Dubray C. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993 21 : 489 514.
42. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002 20 : 4713 4721.
43. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007 63 : 548 561.
44. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006 66 : 7630 7638.
45. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992 51 : 76 89.
46. Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K et al. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol 2007 47 : 1244 1255.
47. Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson US, Karlsson MO. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol 2007 47 : 1159 1171.
48. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 2006 33 : 313 343.
49. Zuideveld KP, Maas HJ, Treijtel N, Hulshof J, van der Graaf PH, Peletier LA et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am J Physiol Regul Integr Comp Physiol 2001 281 : R2059 71.